BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is “One to Watch”
Developing the first off-the-shelf personalized immunotherapy for advanced breast cancer, Bria-OTS. Bria-OTS is designed to provide personalized treatment for ~90% of the advanced breast cancer patients without the high costs and difficult manufacturing associated with personalized treatments. The technology may be applicable to other cancers. Addressing an unmet need by targeting advanced breast cancer, from which an estimated 40,000 women have died in U.S. in 2017 $1 billion-$5 billion market opportunity depending on patient treatment stage Results of two completed proof-of-concept human clinical trials showed rapid tumor shrinkage at multiple sites in advanced breast cancer patients without toxicity associated with…